Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
05/06/2023
Our news
SOME FIGURES
15
brand-name medicines on the market
3.5 million
boxes sold per year
1 million
over one million patients are treated every day
95
employees
4 therapeutic areas
Oncology, Cardio metabolism, Immuno-inflammation and Neuroscience
STAY IN THE LOOP BY SIGNING UP
TO OUR EMAIL LIST!
Get the important information first and fast, directly at your finger tips!
Stay up to date about our products, disease information, treatment options, educational programs, learning activities and patient support programs.